COMMUNIQUÉS West-GlobeNewswire

Mendoza Family Fund Surpasses $1 Million in Partnership with the National Multiple Sclerosis Society
29/10/2026
Milestone marks the culmination of years of grassroots fundraising inspired by the family’s matriarch Elsa Mendoza’s journey with MS NEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) -- The Mendoza Family Fund , created in [...]
Spirited Paw® Pet Supplements Now Available at Chewy
29/10/2026
Launch expands nationwide access to whole food-based nutritional supplements for dogs and cats PALMYRA, Wis., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Standard Process® , a leader in whole food nutrition, today announced that [...]
FEM By UPSA Highlights Growing Body of Research on Non-Hormonal Menopause Support, Including Studies in Breast Cancer Survivors
29/10/2026
Decades of research address key considerations for healthcare professionals discussing non-hormonal menopause options with patients RUEIL-MALMAISON, France, Oct. 29, 2026 (GLOBE NEWSWIRE) -- FEM By UPSA is highlighting [...]
INmune Bio Inc. to Report Third Quarter 2026 Financial Results and Provide Corporate Update on Thursday, November 5th
29/10/2026
Management to host conference call and webcast at 4:30 pm ET on that day BOCA RATON, Fla, Oct. 29, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on [...]
Painletics Launches App to Help With Stiff Necks and Sore Joints
29/10/2026
Painletics App Turns a Short Quiz Into a Daily Routine for the Neck, Back and Joints NEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Painletics has launched a personalized mobility and wellness app built around short guided [...]
20/20 BioLabs to Host November 4 Investor Webinar on OneTest™ Commercial Expansion and Growth Strategy
29/10/2026
CEO Jonathan Cohen to Discuss Laboratory Franchise Model, 2027 Licensing Plans, Potential Acquisitions, FDA Strategy, and Firefighter Cancer Screening Initiatives Webinar to Be Held Wednesday, November 4, 2026 at 12:00 [...]
ALLOX closes $10.5M seed financing and appoints Morten Graugaard as Chair to scale allosteric drug discovery platform and build pipeline
29/10/2026
Financing led by Asabys, with participation from CDTI with its SICC Innvierte and the Institut Català de Finances (ICF) Proceeds will accelerate the expansion of ALLOX’s high-throughput biophysics and AI drug discovery [...]
Exogenus Therapeutics leads a €13 million EU-funded consortium to advance a new secretome-based therapy for osteoarthritis
29/10/2026
ExoCordOA, a f ive-year project, led by Exogenus Therapeutics and backed by Horizon Europe, brings together ten organisations spanning biotechnology, clinical development, regulation, GMP manufacturing, imaging, [...]
Philips launches UniGuide 3D Live Guidance, bringing CT planning into live procedures and extending the capabilities of its Azurion image-guided therapy platform
29/10/2026
October 29, 2026 New CE-marked solution leverages the industry-leading Philips Azurion platform to integrate CT-derived insights and treatment planning directly into the procedural workflow, helping physicians make [...]
Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit
29/10/2026
Positive Phase 2 ACUITY trial findings support Privosegtor’s potential to deliver a first-in-class neuroprotective treatment for patients with optic neuritis and beyond ZUG, Switzerland, October 29 th , 2026 -- Oculis [...]
Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit
29/10/2026
Positive Phase 2 ACUITY trial findings support Privosegtor’s potential to deliver a first-in-class neuroprotective treatment for patients with optic neuritis and beyond ZUG, Switzerland, October 29 th , 2026 -- Oculis [...]
Helsinn announces UK MHRA approval of AKYNZEO® Oral Suspension
29/10/2026
Lugano, Switzerland – October 29 th , 2026 – Helsinn Healthcare SA (“Helsinn”), a global pharmaceutical group focused on supporting patients with cancer and chronic diseases, today announced that the UK Medicines and [...]
RadNet, Inc. Announces Date of its Third Quarter 2026 Financial Results Conference Call
29/10/2026
LOS ANGELES, Oct. 29, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) , a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient [...]
MINES and Associates Earns URAC Full Accreditation for Health Utilization Management
29/10/2026
The designation demonstrates a meaningful commitment to quality health care LITTLETON, Colo., Oct. 29, 2026 (GLOBE NEWSWIRE) -- MINES and Associates (MINES) is proud to announce that it has earned URAC Full [...]
Fortrea Reports Third Quarter 2026 Results
29/10/2026
Sustained commercial momentum, continued margin improvement, and targeted investments strengthen growth foundation Highlights For the three months ended September 30, 2026: Revenues of $691.5 million Book-to-bill ratio [...]
Biosplice Executives to Appear on Health Uncensored with Dr. Drew on Sunday, November 1
29/10/2026
Chief Executive Officer Erich Horsley and Chief Medical Officer Dr. Yusuf Yazici discuss the need for innovation in knee osteoarthritis and the development of lorecivivint, which is now under regulatory review in the [...]
Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
29/10/2026
Pivotal, Phase 3 CHAPTER-3 data selected for late-breaking oral presentation on Saturday, November 14 ZUG, Switzerland, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company [...]
Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026
29/10/2026
DEER PARK, Ill., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026
29/10/2026
Diranersen late-breaking symposium will feature 96-week long-term extension data and additional 76-week biomarker and clinical data from the Phase 2 CELIA study in early Alzheimer's disease Lecanemab presentations will [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum